Abstract. Urinary neutrophil gelatinase-associated lipocalin (uNGAL), urinary N-acetyl-bd-glucosaminidase (NAG)
INTRODUCTION

E
arly determination of allograft function and prognosis could lead to the development of therapies for kidneys with signifi cant ischemiareperfusion injury (IRI) and more effective recipient management, thereby improving outcomes. Unfortunately, the use of baseline characteristics alone (donor and recipient age, etc.) has limited accuracy in predicting outcomes. Recent insights regarding IRI biomarkers in the setting of acute kidney injury (AKI) suggest allograft injury and recovery could be better characterized by these biomarkers. Delayed graft function (DGF) is an important complication of kidney transplantation (KT) that adversely affects allograft survival. Despite substantial improvements in the fi eld of KT, the incidence of DGF is rising with the growing practice of accepting expanded criteria donors to increase transplantation rates [1] [2] [3] [4] [5] [6] . Delayed graft function predisposes kidney graft to acute and chronic rejection, contributes to progressive allograft dysfunction, and increases the risk of premature graft loss [9] [10] [11] .
Reliable biomarkers enabling early discrimination of DGF in kidney transplantations are lacking, which impairs timely therapeutic interventions. Traditionally, acute graft dysfunction is diagnosed by measuring the serum creatinine, but this parameter is an unreliable indicator of kidney function during an episode of acute injury [12] . One of the most promising biomarkers of acute kidney injury is neutrophil gelatinaseassociated lipocalin (NGAL), which is released into the blood from activated neutrophils during infl ammatory processes. In healthy conditions, this lipocalin is found in the urine only in very small amounts. Massive NGAL quantities excreted in the urine (uNGAL) usually indicate damage of proximal tubular cells [14] [15] . Graft injury due to ischemia-reperfusion is an inevitable consequence of KT procedure and can result in varying degrees of early graft dysfunction, which can be considered a form of post-transplantation acute kidney injury. For this reason, several studies investigated the utility of NGAL for the diagnostic and prognostic of acute graft dysfunction following KT [19, 21, 22] . Recently, the prognostic value of uNGAL on graft function in one year after transplantation was also examined and has presented confl icting fi ndings [23, 25, 26] .
In order to support the usefulness of uNGAL, uNAG and serum cystatin C as reliable markers of graft injury and to clarify the role of these promising biomarkers in the prediction of kidney function beyond the fi rst week after transplant, we conducted a prospective study to: (a) evaluate longitudinal changes of uNGAL and uNAG levels over the fi rst week after KTx and identify factors associated with these changes; (b) assess the performance of uNGAL and uNAG in predicting DGF (defi ned as the requirement for dialysis within the fi rst 7 days after transplantation); (c) appraise the long-term prognostic value of urinary NGAL,NAG and alfa-1-microglobulin/creatinine ratio measured within one week post transplantation on kidney allograft function, evaluated by one-year of serum cystatin C and serum creatinine. AKI due to DGF, defi ned as the need for dialysis within the fi rst week after transplantation, complicates 4-10% of live donor and 5-50% of cadaveric kidney trans plants [28] . DGF predisposes the graft to acute rejection [29] , and increases the risk of chronic allograft nephropathy and graft loss and is an in dependent risk factor for suboptimal graft func tion in one year after transplantation. A varie ty of clinical parameters have been proposed for the prediction of DGF based on the preoperative risks, but unfortunately no objective and reliable markers exist for early diagnosis of DGF. Several clinical parameters for the diagnosis of DGF have been applied based on urine output, the rate of creatinine reduction and the need for hemodialysis, but these clinical variables may take sev eral days to be confi rmed. Consequently, ther apeutic interventions that may ameliorate DGF have been ineffective in human studies [2] , at least in part, due to the paucity of early markers for renal dysfunction. Tools for the early diag nosis of DGF following kidney transplantation have been sparse. Consequently, there has been a marked interest in the potential use of ear ly protocol biopsies for the diagnosis, quantita tion, and prediction of injury following cadaver ic transplantation. For example, the number of apoptotic tubular cells in donor biopsies either before [6] or immediately after engraftment [7] has been shown to correlate with early allograft function. Application of the novel bi omarkers of AKI (NGAL, NAG cystatin C) for detection of early allograft dysfunction may prove useful. They could predict the trend in serum creatinine in the post-transplant peri od without the need for biopsy [8] , which allows ear ly initiation of treatment to improve the long-term prognosis.
Human Neutrophil Gelatinase Associated Lipocalin (NGAL) is one of the most extensive ly studied novel biomarkers both in AKI and in kidney transplant dysfunction. It was original ly identifi ed as a component, along with gelati nase (MMP-9), of a disulfi de-linked heterodim er secreted by neutrophils [21] . NGAL can also be secreted from neutrophils as both a 25 kDa monomer and as a 46 kDa disulfi de-linked dim er in the absence of associated gelatinase [16] . It is normally expressed at very small levels in sever al human tissues, including kidneys, lungs, stom ach and colon. NGAL expression is markedly el evated following renal ischemia/reperfusion injury (I/R). It is freely fi ltered by the glomeru lus, completely absorbed by the proximal tubule. AKI causes failure of absorption of the fi ltered NGAL, and more importantly, increased synthe sis of NGAL by the distal nephron comprising the major fraction of urinary NGAL. The injured kidney is not the major source of plasma NGAL, but surprisingly, the distant organs mainly the liver and the lungs, which showed increased ex pression of NGAL mRNA. Its expression is induced in the proximal tubules during the re generation process after kidney injury. Low urinary excretion of NAG is helpful in the di-agnosis of kidney transplant rejection as the amount of excreted NAG depends on the graft mass, and the amount of urinary creatinine depends on the recipient body mass, a low NAG excretion (related to urinary creatinine) could be a surrogate marker of an unfavorable low graft to body-weight ratio, which in turn might be associated with a reduced graft survival.
Cystatin C is a proteinase inhibitor with a low molecular weight. It is produced at a constant rate in all nucleated cells investigated to date and re leased into plasma, freely fi ltered by the glomeru li and nearly completely metabolized in the prox imal tubules. The concentration of serum cystatin C is mainly determined by glomerular fi ltration, which makes cystatin C an ideal endogenous sur rogate marker of kidney function and estimation of GFR [30, 31] . It has been shown to be superior to serum creatinine [31] . The production of cysta tin C has been extensively reported to be inde pendent of and unaffected by sex, age, height, weight, and muscle mass [24] . Cystatin C levels have been found to be infl uenced by abnormal thyroid function, use of immunosuppressive therapy and the presence of systemic infl ammation [29] . Serum cystatin C concentrations have dem onstrated good inverse correlations with radio nuclide-derived measurements of GFR. The di agnostic value of cystatin C as an estimate of GFR has now been investigated in multiple clinical studies [29] . There is a suggestion that cystatin C-based estimates of GFR may perform better in selected patient populations, in particular those with lower serum creatinine concentrations such as elderly patients, children, renal transplant re cipients, cirrhotics and those that are malnour ished.
MATERIAL
The secondary urine samples are taken every day (if necessary twice daily), they are processed chemically, biochemically, and after centrifugation are considered elements of sediment. In the morning 10 ml urine samples were collected for evaluation of lowmolecular proteins (alfa-1-microglobulin), NGAL, NAG and creatinine, and stored at 40 °C until analysis. Samples were analyzed daily from day 0 before the surgery 1, 2, 3, 4, 7 and 31 days after surgery. From the day of the surgery, allograft function was assessed daily with special attention in the fi rst 0, 1, 2, 4, 7 days. The fi rst sample of blood after the operation was received immediately when patients arrived at the intensive care unit, i.e. average delay of 1 hour 52 min. ± 6 minutes after the end of the operation. Samples of blood were always taken at 08:00 pm every day for the next 31 days.
METHODS
Urine samples for urinary NGAL, NAG and alfa-1-microglobulin/creatinine ratio determination were collected 3 to 6 h after surgery (0 or baseline); on the following morning, nearly 8 to 12 h after graft reperfusion (fi rst day); and then on the second [2] , fourth [4] , and seventh day [7] , for a total of fi ve samples for each patient. The same laboratory technician, who was blinded to patient information, performed urinary NGAL measurements using a twostep chemiluminescent microparticle immunoassay on a standardized clinical platform (ARCHITECT, Abbott Diagnostics).
Urinary N-acetyl-β-D-glucosaminidase (NAG) activity was measured in urine by colorimetric assay (Boehringer Manchaim, Germany). This method is using the substrate 3-cresolsulfonphaleinyi-N-acetyl-β-Dglucosaminidine-Na salt, which is hydrolysed in the urine sample by the action of NAG. Serum creatinine levels were determined preoperatively, daily, until hospital discharge, after transplantation to evaluate later graft function. Serum creatinine measurements were performed by Jaffé method (Roche Diagnostics). Cystatin C was measured with a particle enhanced immunonephelometric method (Siemens Diagnostics) at the same time points as uNGAL, except for baseline values.
STATISTICAL ANALYSIS
Data is presented as mean ± SD or as median and is ranged when appropriate after checking for Gaussian distribution. Differences between the two groups were evaluated by the Wilcoxon signed-rank test. Multiple comparisons were performed by the Friedman repeated-measure ANOVA on ranks followed by the Dunn test. Correlation between techniques was evaluated by linear regression and ANOVA. Results with P < 0.05 were considered statistically signifi cant.
RESULTS
During time recruitment 50 patients were enrolled. Baseline data are showed in Table 1 .
At fi rst urine samples were obtained from 48 patients. In the following days, urine samples were collected from 42 patients on the 1-st, 2-nd, 4-th and seventh day. The samples have been examined for serum creatinine and cystatin C and NGAL as NAG in the urine in patients before transplantation and the fi rst following week, was in a stable and delayed graft function ( Table 2 ).The concentration of these biomarkers before transplantation was with particularly high values, corresponding to a patient placed on chronic hemodialysis program. In the fi rst days after transplantation the patients who had after transplantation investigated biomarkers showed concentrations with tendency toward normalization. Transplant patients with DGF in this period maintained high levels of creatinine and uNGAL, which was the reason to part with them for the application of dialysis (biopsy was performed in fi ve patients).
Receiver-operating characteristic (ROC) curves showed that urine NGAL in the fi rst postoperative days were accurate in predicting for DGF. The table shows the resulting sensitivity, specifi city, and predictive values for urine NGAL at concentrations of exclusion, which provided the maximum amount of sensitivity and specifi city. In terms of areas under the curves ROC (AUC), the ability of urine NGAL to predict DGF is moderately right at the beginning and the fi rst day and very accurate in the second, fourth and seventh day (Table 4 ). In the fi rst two days after the transplantation, the diagnostic performance of urine NGAL is better than serum creatinine and quite similar to that of cystatin C. Serum creatinine reduction between the fi rst and second days shown with AUC = 0.58 (0.64-0.92) is a bad representation of urine NGAL for the prediction of TFP.
The changes in the concentration of urinary NGAL are shown in Table 5 . High concentration of urinary NGAL was confi rmed on the fi rst day of transplantation and it showed tendency to decrease afterwards. Between the two groups of patients were found signifi cant, although not so pronounced, changes in creatinine levels. Moreover, we confi rmed that glomerular fi ltration rate of patients with stable graft function signifi cantly improved after three months of follow-up. 
DISCUSSION
Similar to other areas in medicine, in kidney transplantation early diagnosis and timely intervention could improve outcomes. If DGF could be detected in the early hours after surgical procedure, maybe a tailored and more individualized intervention could be achieved. The major fi nding of this study is that uN-GAL is a promising biomarker for allograft dysfunction that can be easily and noninvasively assayed in the early post-transplant period. We prospectively evaluated uNGAL of 40 kidney allograft recipients during the fi rst post-transplant week. At all measured time points, uNGAL levels were consistently higher in Table 4 . Area under the receiver-operating characteristic curve at each time point for urinary NGAL and serum cystatin C for predicting DGF patients who developed DGF, including the earliest levels obtained from the fi rst urine sample collected approximately 3 to 6 h after transplant surgery. At this time, clinical diagnosis of DGF is yet not possible, but a simple and noninvasive test can already recognize kidney dysfunction and stratify patients according to likelihood of requiring post-transplant dialysis.
It would be ideal to diagnose graft dysfunction with an early and highly sensitive biologic marker of renal tubular injury. One of the most promising markers is NGAL, and our fi ndings provide further information for the use of uNGAL as a diagnostic and prognostic tool for DGF. According to our estimation, uNGAL values shortly after transplant surgery will be much higher in patients who went on to develop DGF and will rise further in the following days. In contrast, patients with prompt function will have lower levels, which will decrease consistently during the week. The dynamics of changes in these recipients compared to those who presented DGF is quite different. It seems that, not only the baseline levels, but also the pattern of uNGAL longitudinal changes can refl ect graft dysfunction. Hollmen et al. found initial levels of uNGAL higher in DGF patients, but on the following day a decrease was observed, as it happened with recipients with prompt function [23] . As mentioned before, our study did not confi rm this declining in DGF patients. Recipients who went on to develop DGF had initial higher levels of uNGAL that rise further in the following post transplant days, differing from patients with prompt graft function. Our fi ndings are in agreement with results reported by Hall et al. [24] . It seems that, above and beyond the markedly higher levels of uNGAL in patients with graft dysfunction, the contrasting pattern of uNGAL longitudinal changes can distinguish recipients who will need dialysis in the fi rst week after transplantation. In accordance with previously published data [19, 20, 22] , we confi rmed the good performance of NGAL in predicting graft dysfunction in the early post transplant period. Using ROC analysis, our study also confi rms uNGAL as a good diagnostic marker for identifying patients with graft dysfunction and who subsequently will require dialysis. The AUC-ROC for uNGAL was moderately accurate for DGF prediction within the fi rst day after transplantation, and it was excellent on day 2 and day 4.
We report a superior performance of uNGAL levels for predicting DGF over serum creatinine measured at the same time. Urinary NGAL measured on the fi rst day predicted DGF with an AUC-ROC of 0.93, which is markedly better than an AUC-ROC = 0.76 shown by serum creatinine measured on the same day, and also than an AUC-ROC = 0.83 obtained from creatinine reduction ratio from the fi rst to the second day, but quite similar to cystatin C (0.95), a marker considered more accurately to detect changes in renal function [33] . Furthermore, our analyses also revealed that uNGAL levels predicted DGF, even after adjusting for pretransplant variables known to be traditionally associated with DGF. Besides DGF, the other factors that signifi cantly infl uenced uNGAL levels were previous time of dialysis, recipient's age at time of transplantation and cold ischemia time. These three variables were positively correlated with uNGAL values. Mishra and coworkers have shown that the immunohistochemical staining intensity of NGAL was strongly correlated with cold ischemia time and NGAL expression was significantly increased in deceased donor biopsies [16] . We found that uNGAL levels were higher in graft recipients from deceased donors, but only signifi cantly higher on the second day.
Similarly to other authors [16, 22] , we have chosen to measure NGAL in urine, instead of blood, since uN-GAL represents tubule damage in the kidneys rather than fi ltration from blood. An increased level of NGAL in urine usually indicates injury of proximal tubular cells and seems to be more specifi c compared to serum NGAL, which can be produced by other organs and released into the circulation following a transplant surgery [12] . However, despite the undoubted value of urinary markers of kidney injury, their use in transplant recipients can be also a drawback because of possible transient graft anuria, which may preclude the availability of urine and consequently the lack of samples needed to measure NGAL.
Since allograft rejection during the fi rst week and year after kidney transplantation leads to persistent allograft dysfunction and reduced long-term graft survival, it is important to defi ne a good early predictor of kidney damage which is less invasive than allograft biopsy. Previously, published data determined the urinary NAG excretion in renal-transplant recipients at different times after transplantation and showed a direct correlation between the extent of urinary NAG excretion and both the time after renal transplantation and prednisolone dosage [45] . Increased levels of urinary NAG in some recipients of kidney transplantation are due to the administration of calcineurine inhibitors [44] . In our study, we evaluated NAG activity in urine samples collected during the fi rst year after transplantation. We found no impact of NAG activity in day 1 urine samples on the long-term allograft function. However, levels of this enzyme were higher in patients with DGF. Lack of immediate function of the transplanted kidney usually results from ATN, which mainly affects the proximal tubules. These cells are characterized by high metabolism, and therefore, are especially jeopardized by the ischemia (Burne-Taney et al., 2005) [37] . It seems that the assessment of proximal tubule damage markers could be an effi cient DGF prognostic tool. Matteucci and coworkers (1998) confi rmed the correlation of urinary NAG concentration with early allograft function. Kuzniar et al. observed the early post-transplantation period, and recorded higher urinary NAG concentration in patients that developed ATN [44] . High activity of NAG correlated with deteriorating kidney function throughout the whole observation period contributes for better diagnose of DGF. In the fi rst weeks of the post-transplantation period, kidney tubules are exposed to the IRI, toxicity of the immunosuppressive drugs and acute rejection episodes. Damage to the tubules made by those factors determines the longterm function of the allograft (Nankivell et al., 2004). It seems that the most important factor affecting the kidney tubules is IRI. The results of our study confi rm that urinary NAG activity in samples collected on the 1st day after transplantation is a predictor of DGF occurrence. High activity of NAG is associated with poor long-term allograft function, grade of proteinuria in the early postoperative period and glomerular atrophy in allograft biopsy samples.
Monitoring of NAG urine activity is useful in evaluation of early proximal tubule damage and predicting the long-term function of transplanted kidneys. Similarly, in our study, the evaluation of NAG at timepoints other than during the early postoperative period was not useful to predict the long-term function of the transplanted kidney. This may be due to the fact that the infl ammation process caused by IRI stabilizes in the later period after transplantation, and the high concentration of NAG decreases. The results of our study confi rm that urinary NAG activity in samples collected on the 1st day after transplantation is a predictor of DGF occurrence. High activity of NAG is associated with poor long-term allograft function, grade of proteinuria in the early postoperative period and glomerular atrophy in allograft biopsy samples. Monitoring of NAG urine activity is useful in evaluation of early proximal tubule damage and predicting the long-term function of transplanted kidneys.
